Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (Becton, Dickinson and Company) has appointed Rishi Grover as the new executive vice president and chief integrated supply chain officer, effective July 7, 2022. Grover, who brings over 20 years of experience in manufacturing and supply chain, previously held senior roles at Carrier. He will oversee Supply Chain, Operations, Procurement, Sustainability, and EHS teams and will be part of the BD Executive Leadership Team. Grover succeeds Alexandre Conroy, who is retiring after 31 years with the company.
Summary not available.
BD (Becton, Dickinson and Company) has received CE marking for its BD MAX™ Respiratory Viral Panel (RVP), a diagnostic test that detects SARS-CoV-2, Influenza A + B, and RSV using a single nasal or nasopharyngeal swab. This test enhances diagnostic efficiency, crucial during flu season, by enabling quick differentiation and treatment for these viruses. The BD MAX™ System, which supports this assay, is widely utilized globally for various diagnostic tests. BD plans to seek Emergency Use Authorization from the FDA shortly.
BD (Becton, Dickinson and Company) has announced a voluntary recall of certain lots of Intraosseous Needle Set Kits, Manual Driver Kits, and Powered Drivers. The recall is due to potential issues that could lead to difficulty in needle assembly removal, failure of safety mechanisms, and functional loss of intraosseous access. These defects may cause delays in patient care or increase the risk of needlestick injuries. BD advises customers to review their inventory and temporarily halt usage until further notice.
BD (Becton, Dickinson and Company) announced a collaboration with Mayo Clinic Platform to access a vast collection of de-identified clinical data to enhance post-market surveillance of its products. This partnership aims to accelerate innovation, improve patient care, and leverage real-world data for insights beyond traditional clinical trials.
The Mayo Clinic Platform offers access to data from 10 million patients, including extensive lab results and clinical notes. BD plans to utilize advanced analytics and predictive modeling to enhance product development and regulatory submissions, ultimately improving patient outcomes.
CerTest Biotec and BD (Becton, Dickinson and Company) (NYSE: BDX) have partnered to develop a RT-PCR detection kit for the Monkeypox virus using the BD MAX™ Molecular Diagnostic System. This collaboration aims to leverage the BD MAX™ open system reagent suite to validate the CerTest VIASURE Monkeypox CE/IVD test, enhancing user access to confirmatory testing. The BD MAX™ System can process up to 24 samples in under three hours, streamlining diagnostics for various infections.
BD (Becton, Dickinson and Company) has appointed Simon Campion as the new executive vice president and president of its Medical segment, effective July 1, 2022. Campion, who has extensive experience with BD and previously led the Interventional segment, succeeds Alberto Mas who is retiring. His role will focus on the operational and commercial performance of the Medical segment, aligned with BD’s 2025 strategy. Campion holds a Ph.D. in Mechanical Engineering and an MBA.
BD (Becton, Dickinson and Company) has announced its acquisition of Parata Systems for $1.525 billion. This move aims to expand BD's pharmacy automation technologies across various healthcare settings, including hospitals and retail pharmacies. The acquisition is projected to enhance BD's revenue growth, adjusted operating margins, and adjusted earnings per share immediately. Parata's market, valued at $600 million and expected to grow by 10% annually, aligns with BD's 2025 strategy for smart, connected care.
BD (Becton, Dickinson and Company) (NYSE: BDX) has launched the BD FACSDiscover™ S8 Cell Sorter featuring revolutionary BD CellView™ Image Technology at the ISAC CYTO 2022 conference. This new technology allows researchers to sort and view cells rapidly and accurately, enhancing research in virology, oncology, and other fields. The sorter combines spectral flow cytometry with detailed image analysis, enabling previously unidentifiable cell sorting. This development aims to redefine standards in cell sorting, potentially accelerating medical discoveries and therapeutic advancements.
BD (Becton, Dickinson and Company) announced its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 16, 2022, at 11:00 a.m. Eastern Time. The live webcast will be accessible via the BD investor relations website, with a replay available post-event. As a leading global medical technology company, BD focuses on improving medical discovery and care delivery, supported by a dedicated workforce of 75,000 employees worldwide.